公开(公告)号：US20240132477A1

公开(公告)日：2024-04-25

申请号：US18257136

申请日：2021-12-13

Applicant: PFIZER INC.

Inventor： Scott William Bagley ,  Agustin Casimiro Garcia ,  Jennifer Elizabeth Davoren ,  Rajiah Aldrin Denny ,  Brian Stephen Gerstenberger ,  Frank Eldridge Lovering ,  Mihir Dineshkumar Parikh ,  Joseph Walter Strohbach ,  John Isidro Trujillo

IPC: C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14

Abstract: The invention relates to benzimidazoles of Formula (I)




and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.
The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

公开(公告)号：US11661419B2

公开(公告)日：2023-05-30

申请号：US17126358

申请日：2020-12-18

Applicant: Pfizer Inc.

Inventor： Scott William Bagley ,  Agustin Casimiro-Garcia ,  Xiayun Cheng ,  Jennifer Elizabeth Davoren ,  Rajiah Aldrin Denny ,  Brian Stephen Gerstenberger ,  Frank Eldridge Lovering ,  Mihir Dineshkumar Parikh ,  Joseph Walter Strohbach ,  John Isidro Trujillo

IPC: C07D413/14 ,  A61P17/00 ,  A61K45/06

CPC classification number: C07D413/14 ,  A61K45/06 ,  A61P17/00

Abstract: The invention relates to benzimidazoles of Formula (I)




and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.

The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

公开(公告)号：US20240124439A1

公开(公告)日：2024-04-18

申请号：US18257195

申请日：2021-12-13

Applicant: Pfizer Inc.

Inventor： Scott William Bagley ,  Agustin Casimiro-Garcia ,  Jennifer Elizabeth Davoren ,  Rajiah Aldrin Denny ,  Brian Stephen Gerstenberger ,  Katherine Lin Lee ,  Frank Eldridge Lovering ,  Mihir Dineshkumar Parikh ,  Joseph Walter Strohbach ,  John Isidro Trujillo

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: The invention relates to imidazopyridines of Formula (I)




and pharmaceutically acceptable salts thereof, wherein R0 to R5 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.
The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

公开(公告)号：US11708360B2

公开(公告)日：2023-07-25

申请号：US17192968

申请日：2021-03-05

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Christopher Flick ,  Daniel Wei-Shung Kung ,  Vincent Michael Lombardo ,  James John Mousseau ,  Philippe Marcel Nuhant ,  Ralph Pelton Robinson, Jr. ,  Daniel Copley Schmitt ,  Mark Edward Schnute ,  Atli Thorarensen ,  John Isidro Trujillo ,  Rayomand Jal Unwalla ,  Huixian Wu

IPC: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/6558

CPC classification number: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/65583

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)




or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

公开(公告)号：US20210188829A1

公开(公告)日：2021-06-24

申请号：US17126358

申请日：2020-12-18

Applicant: Pfizer Inc.

Inventor： Scott William Bagley ,  Agustin Casimiro-Garcia ,  Xiayun Cheng ,  Jennifer Elizabeth Davoren ,  Rajiah Aldrin Denny ,  Brian Stephen Gerstenberger ,  Frank Eldridge Lovering ,  Mihir Dineshkumar Parikh ,  Joseph Walter Strohbach ,  John Isidro Trujillo

IPC: C07D413/14 ,  A61K45/06 ,  A61P17/00

Abstract: The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.
The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

公开(公告)号：US10975065B2

公开(公告)日：2021-04-13

申请号：US16576997

申请日：2019-09-20

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Christopher Flick ,  Vincent Michael Lombardo ,  James John Mousseau ,  Philippe Marcel Nuhant ,  Ralph Pelton Robinson, Jr. ,  Mark Edward Schnute ,  Daniel Wei-Shung Kung ,  Daniel Copley Schmitt ,  Atli Thorarensen ,  John Isidro Trujillo ,  Rayomand Jal Unwalla ,  Huixian Wu

IPC: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/6558

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

公开(公告)号：US20200095239A1

公开(公告)日：2020-03-26

申请号：US16576997

申请日：2019-09-20

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Christopher Flick ,  Vincent Michael Lombardo ,  James John Mousseau ,  Philippe Marcel Nuhant ,  Ralph Pelton Robinson, JR. ,  Mark Edward Schnute ,  Daniel Wei-Shung Kung ,  Daniel Copley Schmitt ,  Atli Thorarensen ,  John Isidro Trujillo ,  Rayomand Jal Unwalla ,  Huixian Wu

IPC: C07D413/14 ,  C07D401/12 ,  C07D401/14 ,  C07D417/12 ,  C07D413/12 ,  C07D405/14 ,  C07D417/14 ,  C07F9/6558 ,  A61P29/00

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

公开(公告)号：US20240368144A1

公开(公告)日：2024-11-07

申请号：US18311266

申请日：2023-05-03

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Christopher Flick ,  Daniel Wei-Shung Kung ,  Vincent Michael Lombardo ,  James John Mousseau ,  Philippe Marcel Nuhant ,  Ralph Pelton Robinson, JR. ,  Daniel Copley Schmitt ,  Mark Edward Schnute ,  Atli Thorarensen ,  John Isidro Trujillo ,  Rayomand Jal Unwalla ,  Huixian Wu

IPC: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/6558

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.

公开(公告)号：US20230280220A1

公开(公告)日：2023-09-07

申请号：US18301475

申请日：2023-04-17

Applicant: Pfizer Inc.

Inventor： Scott William Bagley ,  Agustin Casimiro Garcia ,  Xiayun Cheng ,  Jennifer Elizabeth Davoren ,  Rajiah Aldrin Denny ,  Brian Stephen Gerstenberger ,  Frank Eldridge Lovering ,  Mihir Dineshkumar Parikh ,  Joseph Walter Strohbach ,  John Isidro Trujillo

IPC: G01L1/25 ,  G01N23/207

CPC classification number: G01L1/25 ,  G01N23/207

Abstract: The invention relates to benzimidazoles of Formula (1)




and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.
The benzimidazoles of Formula (1) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

公开(公告)号：US20210206757A1

公开(公告)日：2021-07-08

申请号：US17192968

申请日：2021-03-05

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Christopher Flick ,  Daniel Wei-Shung Kung ,  Vincent Michael Lombardo ,  James John Mousseau ,  Philippe Marcel Nuhant ,  Ralph Pelton Robinson, JR. ,  Daniel Copley Schmitt ,  Mark Edward Schnute ,  Atli Thorarensen ,  John Isidro Trujillo ,  Rayomand Jal Unwalla ,  Huixian Wu

IPC: C07D413/14 ,  A61P29/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07F9/6558

Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.